CRP and myeloid sarcoma: The findings encompassed a greater prevalence of arthritis impacting over three joint regions (P = 0.001), prolonged MS duration (P = 0.001), higher DAS28-CRP scores (P = 0.003), increased VAS scores (P < 0.001), elevated CRP levels (P = 0.009), raised ESR (P = 0.012), and an augmented requirement for biologic therapy (P = 0.001) (Table 3, Figure 2).